TABLE 1.
cPA conversion efficiency of recombinants carrying multiple copies of the cloned epoA genea
| P. decumbens strain | FOM (μg/ml) | Increase (fold) |
|---|---|---|
| LP3 | 800 | 1.00 |
| LP3/pFOM13 | 760 | 0.95 |
| LP3/pFOM16 | 780 | 0.98 |
| LP3/pFOM4 TF1 | 1,140 | 1.43 |
| LP3/pFOM4 TF2 | 1,150 | 1.44 |
| LP3/pFOM4 TF3 | 2,460 | 3.08 |
| LP3/pFOM4 TF4 | 1,960 | 2.45 |
| LP3/pFOM4 TF5 | 2,020 | 2.53 |
| LP3/pFOM4 TF6 | 2,120 | 2.65 |
| LP3/pFOM4 TF7 | 3,420 | 4.28 |
| LP3/pFOM4 TF8 | 3,090 | 3.86 |
| LP3/pFOM4 TF9 | 2,040 | 2.55 |
| LP3/pFOM4 TF10 | 2,500 | 3.13 |
a
The efficiency of cPA conversion in P. decumbens LP3 was compared to that in transformants containing pFOM4 (TF1 to -10, containing epoA), pFOM13 (containing disrupted epoA), or pFOM16 (vector control containing the hph cassette cloned into the XbaI site of pUC119). cPA was added (final concentration, 4 mg/ml) to P. decumbens cultures prepared as described in Materials and Methods. Incubation was continued under the same conditions for 7 days. FOM was assayed by HPLC analysis as described in Materials and Methods.